2022 Fiscal Year Final Research Report
Development of detecting assay for anti-myelin oligodendrocyte glycoprotein antibody
| Project/Area Number |
20K07892
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 52020:Neurology-related
|
|---|
| Research Institution | Tohoku Medical and Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 脱髄疾患 / 自己抗体 / 検査法 |
|---|
| Outline of Final Research Achievements |
It is becoming clear that myelin oligodendrocyte glycoprotein (MOG) antibodies are involved in inflammatory demyelinating diseases of the central nervous system, and this is being established as a new disease concept distinct from multiple sclerosis and neuromyelitis optica. Measurement of MOG antibodies is essential for diagnosis, but the current measurement method is complicated and costly, preventing widespread use of the test, and has not yet been covered by insurance. In this study, we developed a new assay for MOG antibodies as a diagnostic marker and analyzed the clinical significance of MOG antibodies in relation to cytokines and other substances in serum and cerebrospinal fluid while conducting a nationwide epidemiological survey.
|
| Free Research Field |
神経内科学
|
| Academic Significance and Societal Importance of the Research Achievements |
MOG抗体関連疾患はMOGADとよばれ、当科において初の全国疫学調査を実施した。これにより全国に1700人程度の患者が存在していることがあきらかになった。また、国際的なMOGADの診断基準が提唱され、今後独立した疾患概念として確立していく疾患である。一方でMOG抗体の測定は保険適用になっておらず、測定法のキット化が必要であり、感度および特異度の高い検査法の確立が求められている。今回の研究により開発を進めているMOG抗体測定法を今後キット化することにより、疾患の診断が容易になるため、臨床的な意義が大きい。
|
